Risk Stratification and Contemporary Therapeutic Strategies in Pediatric Pulmonary Hypertension: A Narrative Review
DOI:
https://doi.org/10.12775/QS.2026.71.75765Keywords
pediatric pulmonary hypertension, risk stratification, targeted therapy, right ventricular dysfunction, biomarkersAbstract
Background: Pediatric pulmonary hypertension (PH) is a rare, heterogeneous disease marked by progressive pulmonary vascular resistance and right ventricular pressure overload, with significant morbidity and mortality. Targeted pharmacotherapy has advanced, yet management is complicated by diverse causes, developmental differences from adult disease, and limited pediatric evidence. Risk stratification is now the foundation for individualized treatment.
Aim: This review summarizes evidence on risk stratification and therapy in pediatric PH, focusing on prognostic tools and targeted treatments supporting personalized management.
Material and methods: We conducted a narrative review of PubMed/MEDLINE literature from January 2020 to mid-2026, using pediatric- and PH-specific search terms, supplemented by manual screening of reference lists. Priority was given to guidelines, registry-based and multicenter cohort studies, and recent work on multidimensional risk assessment, cardiac imaging, invasive hemodynamics, biomarkers, pharmacotherapy, and advanced interventions.
Results: Management has shifted from a disease-oriented toward an individualized, risk-guided approach. Reliable prognosis depends on integrating clinical evaluation, echocardiography, cardiac MRI, invasive hemodynamics, and biomarkers, rather than any single parameter. Dynamic risk stratification enables earlier detection of progression and timely escalation. Pharmacological management increasingly relies on combination therapy targeting nitric oxide, endothelin, and prostacyclin pathways, while emerging agents and interventions expand options for high-risk patients.
Conclusions: Risk stratification is the cornerstone of pediatric PH management. Individualized strategies based on continuous assessment enable earlier intervention, optimized treatment, and appropriate selection of advanced therapies. Further multicenter studies are needed to validate risk models and strengthen treatment guidance.
References
1. Epstein R, Krishnan US. Management of Pulmonary Hypertension in the Pediatric Patient. Cardiol Clin. 2022;40(1):115-127. https://doi.org/10.1016/j.ccl.2021.08.010
2. van Loon RLE, Roofthooft MTR, Hillege HL, ten Harkel ADJ, van Osch-Gevers M, Delhaas T, Kapusta L, Strengers JLM, Rammeloo L, Clur SAB, Mulder BJM, Berger RMF. Pediatric Pulmonary Hypertension in the Netherlands: Epidemiology and Characterization During the Period 1991 to 2005. Circulation. 2011;124(16):1755-1764. https://doi.org/10.1161/CIRCULATIONAHA.110.969584
3. Zijlstra WMH, Douwes JM, Rosenzweig EB, Schokker S, Krishnan U, Roofthooft MTR, Miller-Reed K, Hillege HL, Ivy DD, Berger RMF. Survival Differences in Pediatric Pulmonary Arterial Hypertension: Clues to a Better Understanding of Outcome and Optimal Treatment Strategies. J Am Coll Cardiol. 2014;63(20):2159-2169. https://doi.org/10.1016/j.jacc.2014.02.575
4. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Radegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S. 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Eur Heart J. 2022;43(38):3618-3731. https://doi.org/10.1093/eurheartj/ehac237
5. del Cerro MJ, Abman S, Diaz G, Freudenthal AH, Freudenthal F, Harikrishnan S, Haworth SG, Ivy D, Lopes AA, Raj JU, Sandoval J, Stenmark K, Adatia I. A Consensus Approach to the Classification of Pediatric Pulmonary Hypertensive Vascular Disease: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ. 2011;1(2):286-298. https://doi.org/10.4103/2045-8932.83456
6. Jone PN, Ivy DD, Hauck A, Karamlou T, Truong U, Coleman RD, Sandoval JP, Del Cerro Marin MJ, Eghtesady P, Tillman K, Krishnan US. Pulmonary Hypertension in Congenital Heart Disease: A Scientific Statement From the American Heart Association. Circ Heart Fail. 2023;16(7):e000080. https://doi.org/10.1161/HHF.0000000000000080
7. Ivy D, Rosenzweig EB, Abman SH, Beghetti M, Bonnet D, Douwes JM, Manes A, Berger RMF. Embracing the Challenges of Neonatal and Paediatric Pulmonary Hypertension. Eur Respir J. 2024;64(4):2401345. https://doi.org/10.1183/13993003.01345-2024
8. Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, Ivy DD, Berger RMF. Paediatric Pulmonary Arterial Hypertension: Updates on Definition, Classification, Diagnostics and Management. Eur Respir J. 2019;53(1):1801916. https://doi.org/10.1183/13993003.01916-2018
9. Hansmann G, Koestenberger M, Alastalo TP, Apitz C, Austin ED, Bonnet D, Budts W, D’Alto M, Gatzoulis MA, Hasan BS, Kozlik-Feldmann R, Kumar RK, Lammers AE, Latus H, Michel-Behnke I, Miera O, Morrell NW, Pieles G, Quandt D, Sallmon H, Schranz D, Tran-Lundmark K, Tulloh RMR, Warnecke G, Wahlander H, Weber SC, Zartner P. 2019 Updated Consensus Statement on the Diagnosis and Treatment of Pediatric Pulmonary Hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), Endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant. 2019;38(9):879-901. https://doi.org/10.1016/j.healun.2019.06.022
10. Constantine A, Dimopoulos K, Haworth SG, Muthurangu V, Moledina S. Twenty-Year Experience and Outcomes in a National Pediatric Pulmonary Hypertension Service. Am J Respir Crit Care Med. 2022;206(6):758-766. https://doi.org/10.1164/rccm.202110-2428OC
11. Frank BS, Ivy DD. Pediatric Pulmonary Arterial Hypertension. Pediatr Clin North Am. 2020;67(5):903-921. https://doi.org/10.1016/j.pcl.2020.06.005
12. Sullivan RT, Raj JU, Austin ED. Recent Advances in Pediatric Pulmonary Hypertension: Implications for Diagnosis and Treatment. Clin Ther. 2023;45(9):901-912. https://doi.org/10.1016/j.clinthera.2023.07.001
13. Lammers AE, Marek J, Diller GP, Haworth SG, Moledina S. Prognostic Value of Transthoracic Echocardiography in Children With Pulmonary Arterial Hypertension. J Am Heart Assoc. 2023;12(6):e023118. https://doi.org/10.1161/JAHA.121.023118
14. Ta HT, Critser PJ, Schäfer M, Ollberding NJ, Taylor MD, Di Maria MV, Hirsch R, Ivy DD, Frank BS. Ventricular Global Function Index Is Associated With Clinical Outcomes in Pediatric Pulmonary Hypertension. J Cardiovasc Magn Reson. 2023;25(1):39. https://doi.org/10.1186/s12968-023-00947-8
15. Torun EG, Özdemiroğlu N, Bağrul D, Ece İ. Pulmonary Artery Pulsatility Index: A Novel Marker for Risk Assessment and Prognosis in Pediatric Idiopathic Pulmonary Arterial Hypertension. Pediatr Cardiol. 2026;47(4):1788-1797. https://doi.org/10.1007/s00246-025-03970-x
16. Smits FE, Lokhorst C, Haarman MG, Ploegstra MJ, Berger RMF, Douwes JM. The Pulmonary Artery Pulsatility Index Provides No Additional Prognostic Information in Pediatric Pulmonary Arterial Hypertension. Children (Basel). 2024;11(10):1152. https://doi.org/10.3390/children11101152
17. Griffiths M, Yang J, Simpson CE, Vaidya D, Nies M, Brandal S, Damico R, Ivy DD, Austin ED, Pauciulo MW, Lutz KA, Rosenzweig EB, Hirsch R, Yung D, Nichols WC, Everett AD. ST2 Is a Biomarker of Pediatric Pulmonary Arterial Hypertension Severity and Clinical Worsening. Chest. 2021;160(1):297-306. https://doi.org/10.1016/j.chest.2021.01.085
18. Elesawy SA, El-Serogy HA, Sorour EA, Zoair AM. Plasma Mid-Regional Proadrenomedullin Level in Children With Pulmonary Hypertension Associated With CHD. Cardiol Young. 2023;33(12):2567-2573. https://doi.org/10.1017/S1047951123000471
19. Pamukçu Ö, Ay D, Üzüm K, Barlakketi D, Köse M, Baykan A, Sunkak S, Narin N. Role of Kallistatin in Pediatric Patients With Pulmonary Arterial Hypertension. Turk J Pediatr. 2020;62(3):405-410. https://doi.org/10.24953/turkjped.2020.03.007
20. Rodriguez Ogando A, Sabaté-Rotés A, Moya Bonora A, Albert de la Torre L, Espín López JM, Labrandero de Lera C, del Cerro Marin MJ. Macitentan in Children With Pulmonary Arterial Hypertension: A Multicenter Experience. Pediatr Cardiol. 2026;47(4):1572-1580. https://doi.org/10.1007/s00246-025-03937-y
21. Berger RMF, Ivy DD, Borissoff JI, Cerovic S, Csonka D, Remenova T, Richard D, Villeneuve M, Beghetti M. Macitentan in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial. J Pediatr. 2026;293:115057. https://doi.org/10.1016/j.jpeds.2026.115057
22. Douwes JM, Zijlstra WMH, Rosenzweig EB, Ploegstra MJ, Krishnan US, Haarman MG, Roofthooft MTR, Postmus D, Hillege HL, Ivy DD, Berger RMF. Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine. Ann Am Thorac Soc. 2022;19(2):227-237. https://doi.org/10.1513/AnnalsATS.202012-1563OC
23. He Y, Li Q, Zhang C, Keller BB, Gu H. Treprostinil Effectiveness in Higher-Risk Pediatric Patients With Idiopathic and Heritable Pulmonary Arterial Hypertension. Can J Cardiol. 2024;40(4):613-621. https://doi.org/10.1016/j.cjca.2023.11.004
24. Frank BS, Gentzler ER, Avitabile CM, Miller-Reed K, Pan Z, Rosenzweig EB, Ivy DD, Krishnan US. Safety and Effectiveness of Selexipag in Pediatric Pulmonary Hypertension: A Retrospective Multicenter Cohort Study. J Pediatr. 2024;275:114221. https://doi.org/10.1016/j.jpeds.2024.114221
25. Willmann S, Keller AK, Meyer M, van der Mey D, Wirsching G, Zhang Y, Drenth HJ, Keunecke A, Vendel E, Saleh S. Population Pharmacokinetics of Riociguat in a Pediatric Population (Aged ≥6 Years) With Pulmonary Arterial Hypertension. Pediatr Pulmonol. 2023;58(3):908-917. https://doi.org/10.1002/ppul.26277
26. Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grunig E, Kopec G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023;388(16):1478-1490. https://doi.org/10.1056/NEJMoa2213558
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Agnieszka Zielińska, Zuzanna Zofia Kamińska, Gabriela Senda, Michał Gorlo
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 51
Number of citations: 0
